Liver X receptor agonist treatment attenuates cardiac dysfunction in type 2 diabetic db/db mice
Conclusions:
Our data demonstrate that GW3965 exerts a cardioprotective effect against DCM by (at least in part) attenuating insulin resistance, modulating Akt and MAP kinases pathways, and reducing oxidative/nitrative stress and inflammatory response. These findings strongly suggest that LXR agonist may have therapeutic potential in treating DCM.
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Qing HeJun PuAncai YuanTianbao YaoXiaoying YingYichao ZhaoLongwei XuHuan TongBen He Source Type: research
More News: Cardiac Catheterization | Cardiology | Cardiomyopathy | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Genetics | Heart | Insulin | Liver | Pathology | Physiology | Study | Urology & Nephrology